Healthcare provider profile · identity verified

Sandra K Oza, MD

Internal Medicine · BRONX, NY · NPI 1366604936

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	397	103
Albuterol Sulfate Hfa	Albuterol Sulfate	283	47
Gabapentin	Gabapentin	183	46
Lisinopril	Lisinopril	159	43
Metformin Hcl	Metformin Hcl	157	37
Eliquis	Apixaban	152	26
Ammonium Lactate	Ammonium Lactate	148	24
Famotidine	Famotidine	143	39
Amlodipine Besylate	Amlodipine Besylate	137	36
Nifedipine Er	Nifedipine	123	39
Fluticasone Propionate	Fluticasone Propionate	122	29
Hydrochlorothiazide	Hydrochlorothiazide	119	33
Omeprazole	Omeprazole	115	26
Diclofenac Sodium	Diclofenac Sodium	110	36
Meclizine Hcl	Meclizine Hcl	106	19
Losartan Potassium	Losartan Potassium	97	28
Levothyroxine Sodium	Levothyroxine Sodium	96	23
Jardiance	Empagliflozin	92	17
Metoprolol Succinate	Metoprolol Succinate	91	26
Carvedilol	Carvedilol	89	23
Furosemide	Furosemide	83	23
Duloxetine Hcl	Duloxetine Hcl	75	19
Pantoprazole Sodium	Pantoprazole Sodium	72	24
Triamcinolone Acetonide	Triamcinolone Acetonide	66	14
Naproxen	Naproxen	62	13
Trulicity	Dulaglutide	62	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	56	18
Alcohol Prep Pads	Alcohol Antiseptic Pads	53	16
Clopidogrel	Clopidogrel Bisulfate	53	suppressed
Ketoconazole	Ketoconazole	53	suppressed
Rybelsus	Semaglutide	52	suppressed
Januvia	Sitagliptin Phosphate	51	15
Tamsulosin Hcl	Tamsulosin Hcl	51	15
Sucralfate	Sucralfate	50	suppressed
Montelukast Sodium	Montelukast Sodium	48	12
Pregabalin	Pregabalin	47	suppressed
Clotrimazole	Clotrimazole	46	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	12
Ozempic	Semaglutide	43	suppressed
Pravastatin Sodium	Pravastatin Sodium	42	suppressed
Simvastatin	Simvastatin	42	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	13
Lidocaine	Lidocaine	40	suppressed
Nystatin	Nystatin	39	suppressed
Chlorthalidone	Chlorthalidone	38	suppressed
Finasteride	Finasteride	37	suppressed
Novolog Flexpen	Insulin Aspart	37	suppressed
Azelastine Hcl	Azelastine Hcl	36	suppressed
Hydrocortisone	Hydrocortisone	36	suppressed
Alendronate Sodium	Alendronate Sodium	35	12
Mirtazapine	Mirtazapine	35	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	35	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	34	11
Ezetimibe	Ezetimibe	33	suppressed
Ibuprofen	Ibuprofen	33	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	33	suppressed
Hydralazine Hcl	Hydralazine Hcl	32	11
Spironolactone	Spironolactone	32	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	32	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	31	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	29	suppressed
Atenolol	Atenolol	29	suppressed
Restasis	Cyclosporine	28	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	28	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Tramadol Hcl	Tramadol Hcl	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Incruse Ellipta	Umeclidinium Bromide	25	suppressed
Single Use Swab	Alcohol Antiseptic Pads	25	suppressed
Latanoprost	Latanoprost	24	suppressed
Allopurinol	Allopurinol	22	suppressed
Levetiracetam	Levetiracetam	22	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	22	suppressed
Azathioprine	Azathioprine	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	21	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Estradiol	Estradiol	18	suppressed
Lactulose	Lactulose	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Folic Acid	Folic Acid	15	suppressed
Procto-Med Hc	Hydrocortisone	15	suppressed
Telmisartan	Telmisartan	15	suppressed
Trazodone Hcl	Trazodone Hcl	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Admelog Solostar	Insulin Lispro	14	suppressed
Baclofen	Baclofen	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
True Comfort Pro Alcohol Pads	Alcohol Antiseptic Pads	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Sertraline Hcl	Sertraline Hcl	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Fosinopril Sodium	Fosinopril Sodium	11	suppressed
Linzess	Linaclotide	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Nyamyc	Nystatin	11	suppressed
Opzelura	Ruxolitinib Phosphate	11	suppressed
Polymyxin B Sul-Trimethoprim	Polymyxin B Sulf/Trimethoprim	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error